Fentanyl
Other / unclassified targets OPRM1 via activation
Regulatory milestones approvals, filings & regulatory actions · 11 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (3) | US (FDA) | DURAGESIC-100 | — | 2003-05-20 – 2018-01-24 | fda.gov ↗ |
| Label expansion | US (FDA) | IONSYS | — | 2015-04-30 | fda.gov ↗ |
| Label expansion | US (FDA) | FENTORA | — | 2013-02-21 | fda.gov ↗ |
| Refused (EMA) | EU (EMA) | Ionsys | — | 2008-07-25 | europa.eu ↗ |
| Label expansion | US (FDA) | ACTIQ | — | 2007-02-07 | fda.gov ↗ |
| Approved | EU (EMA) | Ionsys | — | 2006-01-24 | europa.eu ↗ |
| Label expansions (2) | US (FDA) | FENTANYL | — | 1995-10-30 – 1996-05-20 | fda.gov ↗ |
| Approved | US (FDA) | SUBLIMAZE PRESERVATIVE FREE | — | 1968-02-19 | fda.gov ↗ |
Trials 396 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 05 trials | ||||||
| Phase 0 | NCT06561672 | Sep 2024 → Mar 2025 overdue | — | Zagazig University | Enrolling by invitation | No outcome recorded |
| Phase 0 | NCT06435949 | Jul 2024 → Jun 2026 | — | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT05579509 | Oct 2022 → May 2024 | — | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 0 | NCT02209610 | Jul 2015 → Jan 2017 | heart failure | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 0 | NCT01853449 | Jun 2013 → Aug 2014 | — | McGill University | Completed | No outcome recorded |
| Phase 125 trials | ||||||
| Phase 1 | NCT06953453 | Sep 2025 → Jul 2026 overdue | cancer | Lee's Pharmaceutical Limited | Recruiting | No outcome recorded |
| Phase 1 | NCT06281951 | Apr 2024 → Jun 2027 expected | — | University Hospital, Rouen | Recruiting | No outcome recorded |
| Phase 1 | NCT05429567 | Mar 2021 → Feb 2022 | — | Egymedicalpedia | Completed | No outcome recorded |
| Phase 1 | NCT04062123 | Jul 2020 → Apr 2024 | — | Keith M Vogt | Completed | No outcome recorded |
| Phase 1 | NCT04823390 | Sep 2019 → Feb 2021 | — | Cairo University | Completed | No outcome recorded |
| Phase 1 | NCT04011098 | Jul 2019 → Nov 2020 | obstetric disorder | University of Saskatchewan | Terminated | No outcome recorded |
| Phase 1 | NCT03824314 | May 2019 → Jan 2020 | — | Mohamed Abdelrady Mohamed | Completed | No outcome recorded |
| Phase 1 | NCT03747341 | Mar 2018 → Jan 2019 | substance-related disorder | Indivior Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02641340 | Jan → Mar 2016 | — | INSYS Therapeutics Inc | Completed | No outcome recorded |
| Phase 1 | NCT02608320 | Nov 2015 → Apr 2016 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02576353 | Oct → Nov 2015 | — | INSYS Therapeutics Inc | Completed | No outcome recorded |
| Phase 1 | NCT01756651 | Feb 2013 → May 2016 | — | Richard C Reznichek, MD | Completed | No outcome recorded |
| Phase 1 | NCT01750060 | Dec 2012 → Mar 2013 | — | Incline Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01717157 | Aug → Nov 2012 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01497288 | Nov → Dec 2011 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT01593397 | Nov 2011 → Sep 2017 | obesity disorder | Stanford University | Completed | No outcome recorded |
| Phase 1 | NCT01780233 | Apr → May 2007 | — | INSYS Therapeutics Inc | Completed | No outcome recorded |
| Phase 1 | NCT00648414 | Oct 2006 | — | Mylan Pharmaceuticals Inc | Terminated | No outcome recorded |
| Phase 1 | NCT00857753 | Sep → Oct 2006 | — | Sandoz | Completed | No outcome recorded |
| Phase 1 | NCT00402350 | Apr → Nov 2006 | — | Alexza Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00886002 | Nov 2004 → Jan 2005 | — | Janssen-Cilag A.G., Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT00864565 | Jun 2003 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00714558 | Apr → May 2003 | — | Alza Corporation | Completed | No outcome recorded |
| Phase 1 | NCT00794209 | Mar → May 2003 | — | YM BioSciences | Completed | No outcome recorded |
| Phase 1 | NCT00708318 | Oct → Nov 2001 | — | YM BioSciences | Completed | No outcome recorded |
| Phase 1/29 trials | ||||||
| Phase 1/2 | NCT07112430 | Sep 2026 → Mar 2028 expected | retinopathy of prematurity | Marsha Campbell-Yeo | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07672301 | Mar 2026 → Jun 2027 expected | — | University of Chicago | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06031883 | Feb 2023 → Dec 2024 | — | Minia University | Completed | No outcome recorded |
| Phase 1/2 | NCT05037539 | Jun → Dec 2021 | bone pain, periodic | Department of Medical Services Ministry of Public Health of Thailand | Completed | No outcome recorded |
| Phase 1/2 | NCT04713189 | Mar → Dec 2021 | — | Lee's Pharmaceutical Limited | Unknown | No outcome recorded |
| Phase 1/2 | NCT04136548 | Jun 2019 → Nov 2020 | — | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT01515566 | Apr 2012 → Apr 2013 | — | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT01248611 | Jan → May 2011 | cancer, chronic pain syndrome | St. Olavs Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT00685295 | Aug 2008 → Feb 2009 | — | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 230 trials | ||||||
| Phase 2 | NCT07224620 | Nov 2025 → May 2026 | — | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT05057689 | Sep → Oct 2025 | acute stress disorder, anxiety | Nationwide Children's Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT06531759 | Sep 2024 → Sep 2025 overdue | — | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05367336 | Aug 2022 → Feb 2025 | qualitative platelet defect | Corewell Health South | Terminated | No outcome recorded |
| Phase 2 | NCT05531422 | Oct 2021 → Mar 2023 | — | Lee's Pharmaceutical Limited | Completed | No outcome recorded |
| Phase 2 | NCT04204967 | Feb 2021 → Apr 2024 | respiratory failure | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Completed | No outcome recorded |
| Phase 2 | NCT03809455 | Feb 2020 → Feb 2022 | — | UNICANCER | Withdrawn | No outcome recorded |
| Phase 2 | NCT03293927 | Apr 2018 → Jul 2019 | delirium | Duke University | Withdrawn | No outcome recorded |
| Phase 2 | NCT03071744 | Mar 2017 → Mar 2018 | bone neoplasm | Joseph Ma | Terminated | No outcome recorded |
| Phase 2 | NCT02915978 | Dec 2016 → Feb 2017 | — | INSYS Therapeutics Inc | Completed | No outcome recorded |
| Phase 2 | NCT02514252 | Feb 2016 → Nov 2019 | — | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT02454751 | Oct 2015 → Jun 2017 | congestive heart failure | St. Boniface Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01856114 | May 2014 → Dec 2019 | cancer of unknown primary site | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01832402 | Jun 2013 → Nov 2019 | — | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT02172014 | Jun 2013 → Jan 2015 | — | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04635852 | Mar 2013 → Nov 2014 | cancer | University of Cologne | Completed | No outcome recorded |
| Phase 2 | NCT00807209 | Dec 2008 → Feb 2009 | — | Pacira Pharmaceuticals, Inc | Terminated | No outcome recorded |
| Phase 2 | NCT02430090 | Nov 2006 → Mar 2007 | — | Ankara City Hospital Bilkent | Completed | No outcome recorded |
| Phase 2 | NCT00236093 | Oct → Dec 2006 | cancer, sickle cell disease | Cephalon | Completed | No outcome recorded |
| Phase 2 | NCT00355628 | Jul 2006 → Jul 2007 | cancer | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00345735 | May 2006 → Oct 2007 | cancer | Nycomed | Completed | No outcome recorded |
| Phase 2 | NCT00478101 | Feb 2006 → Apr 2007 | — | Gachon University Gil Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00278824 | Jan → Aug 2006 | — | ZARS Pharma Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00216658 | Dec 2004 → Sep 2005 | neurological pain disorder | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 2 | NCT00236041 | Apr 2004 → Aug 2006 | cancer | Cephalon | Completed | No outcome recorded |
| Phase 2 | NCT00108771 | Apr 2004 → Sep 2006 | — | ZARS Pharma Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00108446 | Oct 2003 → Mar 2006 | irritable bowel syndrome | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 2 | NCT00650182 | Jan → Jul 2003 | chronic pain syndrome | Alza Corporation | Completed | No outcome recorded |
| Phase 2 | NCT00000273 | Aug 1995 → Nov 2005 | heroin dependence | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 2 | NCT02137525 | ? → Jun 2017 | — | INSYS Therapeutics Inc | Withdrawn | No outcome recorded |
| Phase 2/312 trials | ||||||
| Phase 2/3 | NCT06799442 | Mar → Dec 2025 overdue | — | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05145543 | Dec 2021 → Mar 2022 | — | Assiut University | Unknown | No outcome recorded |
| Phase 2/3 | NCT04971759 | Dec 2019 → Dec 2020 | — | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT04004117 | Jul → Dec 2019 | chronic obstructive pulmonary disease | McGill University Health Centre/Research Institute of the McGill University Health Centre | Terminated | No outcome recorded |
| Phase 2/3 | NCT02489019 | Feb 2018 → Jul 2020 | hypotensive disorder | Loyola University | Unknown | No outcome recorded |
| Phase 2/3 | NCT03260283 | Aug 2017 → Nov 2018 | — | Saint Savvas Anticancer Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT03167905 | Jun 2017 → Jul 2021 overdue | postpartum depression | KK Women's and Children's Hospital | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT02597478 | Jan 2016 → Sep 2018 | cancer of unknown primary site | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2/3 | NCT02617199 | Nov 2015 → Dec 2016 | acute pancreatitis | Hospital General Naval de Alta Especialidad - Escuela Medico Naval | Unknown | No outcome recorded |
| Phase 2/3 | NCT02298582 | Dec 2014 → Oct 2017 | — | University Hospital, Grenoble | Completed | No outcome recorded |
| Phase 2/3 | NCT00286221 | Mar 2006 → Jul 2010 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2/3 | NCT01648595 | Jan → Aug 2006 | — | Mashhad University of Medical Sciences | Terminated | No outcome recorded |
| Phase 382 trials | ||||||
| Phase 3 | NCT07076368 | Oct 2025 → Jul 2026 overdue | pregnancy disorder | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 3 | NCT06464146 | Feb 2025 → Feb 2028 expected | — | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT07019805 | Sep 2024 → Mar 2025 | acute hypotension | Indonesia University | Completed | No outcome recorded |
| Phase 3 | NCT06590870 | Aug 2024 → Feb 2025 | — | Mount Sinai Hospital, Canada | Completed | No outcome recorded |
| Phase 3 | NCT06051227 | Jan 2024 → Mar 2026 overdue | — | Academic Medical Center - University of Amsterdam | Recruiting | No outcome recorded |
| Phase 3 | NCT05491187 | Sep 2022 → Apr 2023 | — | Tribhuvan University Teaching Hospital, Institute Of Medicine. | Completed | No outcome recorded |
| Phase 3 | NCT05137184 | Nov 2021 → Apr 2023 | — | Oslo University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT04621110 | Jun → Sep 2021 | childhood malignant neoplasm | University of Sao Paulo General Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04188418 | Oct 2020 → Aug 2027 expected | cancer, hematopoietic and lymphoid cell neoplasm | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04533243 | Sep 2020 → Aug 2022 | — | Fujian Cancer Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04011150 | Aug 2020 → Dec 2025 overdue | — | KK Women's and Children's Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT04128540 | Feb 2020 → Jul 2021 | aorta coarctation | Cairo University | Completed | No outcome recorded |
| Phase 3 | NCT03872700 | Aug 2019 → Dec 2022 | abscess | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT04026022 | Jun 2019 → Mar 2020 | — | Medical University of Graz | Completed | No outcome recorded |
| Phase 3 | NCT03639389 | Jan 2019 → Mar 2022 | — | Karolinska Institutet | Completed | No outcome recorded |
| Phase 3 | NCT02138409 | Dec 2017 → Jan 2018 | chronic pain syndrome | INSYS Therapeutics Inc | Withdrawn | No outcome recorded |
| Phase 3 | NCT03214510 | Oct 2017 → Jul 2027 expected | hepatobiliary disorder | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03063359 | May 2017 → Jul 2018 | — | University Hospital, Montpellier | Terminated | No outcome recorded |
| Phase 3 | NCT01906073 | Jan 2017 → Dec 2020 | cancer | Norwegian University of Science and Technology | Withdrawn | No outcome recorded |
| Phase 3 | NCT03005899 | Nov 2016 → Jul 2017 | — | SymBio Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT02395653 | Jun 2015 → Sep 2016 | — | The Medicines Company | Completed | No outcome recorded |
| Phase 3 | NCT02426697 | May 2015 → Apr 2020 | bone neoplasm | Centre Henri Becquerel | Completed | No outcome recorded |
| Phase 3 | NCT01980498 | Sep 2014 → Sep 2015 | — | L.Molteni & C. dei F.lli Alitti-Soc. di Esercizio S.p.A. | Withdrawn | No outcome recorded |
| Phase 3 | NCT02079090 | Jul 2014 → Jun 2017 | — | University of British Columbia | Completed | No outcome recorded |
| Phase 3 | NCT02084355 | Apr 2014 → Dec 2015 | cancer | Gyeongsang National University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02145975 | Jan → Apr 2014 | — | Universidad de Antioquia | Completed | No outcome recorded |
| Phase 3 | NCT02004899 | Dec 2013 → Oct 2014 | — | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| Phase 3 | NCT02241486 | Sep 2013 → Sep 2014 | — | Loyola University | Terminated | No outcome recorded |
| Phase 3 | NCT01549002 | Jan 2012 → Apr 2013 | abscess | Columbia University | Completed | No outcome recorded |
| Phase 3 | NCT01842893 | Nov 2011 → Jul 2012 | cancer | Ethypharm | Completed | No outcome recorded |
| Phase 3 | NCT01493245 | Oct 2011 → Mar 2013 | chronic pain syndrome | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 3 | NCT01429051 | Aug 2011 → Jan 2013 | cancer | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT01270659 | May 2011 → Oct 2014 | — | University of Oklahoma | Completed | No outcome recorded |
| Phase 3 | NCT01326689 | Mar 2011 → Jun 2012 | — | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00959400 | Nov 2009 → Jun 2011 | — | Cristália Produtos Químicos Farmacêuticos Ltda. | Withdrawn | No outcome recorded |
| Phase 3 | NCT03713762 | Oct → Nov 2009 | — | Centro Medico Docente la Trinidad | Completed | No outcome recorded |
| Phase 3 | NCT00956254 | Oct 2009 → Oct 2010 | mucositis | INSYS Therapeutics Inc | Completed | No outcome recorded |
| Phase 3 | NCT03365817 | Feb 2009 → Dec 2014 | chronic pain syndrome, substance-related disorder | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 3 | NCT01008618 | Jan 2009 → Feb 2010 | chronic pain syndrome, osteoarthritis | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 3 | NCT00813488 | Dec 2008 → Nov 2009 | chronic pain syndrome | Cephalon | Completed | No outcome recorded |
| Phase 3 | NCT01008553 | Dec 2008 → Mar 2010 | complex regional pain syndrome, postherpetic neuralgia | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 3 | NCT00822614 | Dec 2008 → Dec 2009 | — | Akela Pharma, Inc. | Unknown | No outcome recorded |
| Phase 3 | NCT00788372 | Nov 2008 → Nov 2010 | chronic pain syndrome | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 3 | NCT00666393 | Oct 2008 → Dec 2010 | neuropathy, painful | Alza Corporation | Withdrawn | No outcome recorded |
| Phase 3 | NCT00696137 | Jun 2008 → Jul 2009 | respiratory underresponsiveness to hypoxia and hypercapnia | BioDelivery Sciences International | Completed | No outcome recorded |
| Phase 3 | NCT00683995 | Mar 2008 → Jul 2009 | — | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00684632 | Mar 2008 → Apr 2009 | — | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00635063 | Feb 2008 → ? | cancer | Sosei | Terminated | No outcome recorded |
| Phase 3 | NCT00641667 | Jan → Jun 2008 | cancer | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 3 | NCT00741351 | Dec 2007 → Mar 2009 | — | Azienda Ospedaliera San Gerardo di Monza | Completed | No outcome recorded |
| Phase 3 | NCT00538863 | Dec 2007 → Oct 2010 | cancer | INSYS Therapeutics Inc | Completed | No outcome recorded |
| Phase 3 | NCT00538850 | Oct 2007 → Feb 2010 | cancer | INSYS Therapeutics Inc | Completed | No outcome recorded |
| Phase 3 | NCT00463047 | Jul 2007 → Feb 2009 | chronic pain syndrome | Cephalon | Completed | No outcome recorded |
| Phase 3 | NCT00496392 | Jan 2007 → Aug 2008 | — | Nycomed | Completed | No outcome recorded |
| Phase 3 | NCT00458510 | Jan 2007 → Oct 2011 | — | Archimedes Development Ltd | Completed | No outcome recorded |
| Phase 3 | NCT00459277 | Dec 2006 → Jul 2008 | — | Archimedes Development Ltd | Completed | No outcome recorded |
| Phase 3 | NCT00387010 | Dec 2006 → Oct 2007 | chronic pain syndrome | Cephalon | Terminated | No outcome recorded |
| Phase 3 | NCT00405444 | Nov 2006 → Sep 2008 | — | The Hospital for Sick Children | Completed | No outcome recorded |
| Phase 3 | NCT00343733 | Aug 2006 → Jul 2007 | — | Cephalon | Completed | No outcome recorded |
| Phase 3 | NCT00362583 | Jun 2006 → Oct 2007 | cancer | Nycomed | Completed | No outcome recorded |
| Phase 3 | NCT00293020 | Feb 2006 → Jun 2008 | cancer | BioDelivery Sciences International | Completed | No outcome recorded |
| Phase 3 | NCT00293033 | Feb 2006 → Apr 2007 | cancer | BioDelivery Sciences International | Completed | No outcome recorded |
| Phase 3 | NCT00262678 | Dec 2005 → Dec 2008 | cancer | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00263575 | Dec 2005 → Dec 2008 | cancer | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00241332 | Oct 2005 → Jul 2006 | — | Ullevaal University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00214942 | Sep 2005 → Mar 2006 | chronic pain syndrome | Cephalon | Completed | No outcome recorded |
| Phase 3 | NCT00214955 | Sep 2005 → May 2006 | neuropathy, painful | Cephalon | Completed | No outcome recorded |
| Phase 3 | NCT00126789 | Aug 2005 → Jul 2007 | cancer | ZARS Pharma Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00126763 | Jul 2005 → Dec 2006 | — | ZARS Pharma Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00216684 | May 2005 → Sep 2006 | chronic pain syndrome | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 3 | NCT00228605 | Mar 2005 → May 2007 | diabetic neuropathy, migraine disorder, osteoarthritis | Cephalon | Completed | No outcome recorded |
| Phase 3 | NCT00105287 | Jan 2005 → Sep 2006 | cancer | Cephalon | Completed | No outcome recorded |
| Phase 3 | NCT00279344 | Sep 2004 → Aug 2007 | — | Nycomed | Completed | No outcome recorded |
| Phase 3 | NCT00236145 | Jun 2004 → Aug 2005 | — | Cephalon | Completed | No outcome recorded |
| Phase 3 | NCT00266539 | Apr 2004 → Apr 2005 | — | Alza Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00105937 | Apr 2004 → Nov 2006 | cancer | Cephalon | Completed | No outcome recorded |
| Phase 3 | NCT00264485 | Mar 2004 → Apr 2005 | — | Alza Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00271466 | Feb 2000 → Apr 2002 | chronic pain syndrome | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 3 | NCT00271414 | Mar 1999 → Mar 2001 | chronic pain syndrome | Janssen Pharmaceutica N.V., Belgium | Completed | No outcome recorded |
| Phase 3 | NCT00271453 | Feb 1996 → Oct 1998 | chronic pain syndrome | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 3 | NCT00269763 | Oct 1987 → Apr 1988 | cancer | Alza Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00269737 | May 1986 → Feb 1988 | cancer | Alza Corporation | Completed | No outcome recorded |
| Phase 4117 trials | ||||||
| Phase 4 | NCT07684365 | Aug 2026 → Dec 2027 expected | — | Beth Israel Deaconess Medical Center | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07670052 | Aug 2026 → Jun 2027 expected | — | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07556523 | Mar 2026 → Apr 2028 expected | aortic valve stenosis | David Lyubashevsky | Recruiting | No outcome recorded |
| Phase 4 | NCT07116564 | Aug 2025 → Aug 2026 overdue | — | Aga Khan University | Recruiting | No outcome recorded |
| Phase 4 | NCT06793358 | Jul 2025 → Feb 2026 | — | Indiana University | Withdrawn | No outcome recorded |
| Phase 4 | NCT06696586 | Jul 2025 → Dec 2026 expected | — | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06763705 | Jun → Dec 2025 | — | Qassim Health Cluster | Completed | No outcome recorded |
| Phase 4 | NCT06752629 | Jan 2025 → Jan 2026 overdue | gallbladder disorder | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06720506 | Jan 2025 → Jan 2026 overdue | — | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06722963 | Jan 2025 → Jan 2026 overdue | — | Assiut University | Not yet recruiting | No outcome recorded |
| Show all 117 trials opens the full record — a long page | ||||||
| Phase not applicable116 trials | ||||||
| — | NCT07435493 | Nov 2026 expected | adenoid hypertrophy, obstructive sleep apnea syndrome | Ain Shams University | Not yet recruiting | No outcome recorded |
| — | NCT07610408 | Jun → Sep 2026 expected | — | Ankara Etlik City Hospital | Recruiting | No outcome recorded |
| — | NCT07347886 | Jan → Jul 2026 overdue | cataract | Istanbul University - Cerrahpasa | Not yet recruiting | No outcome recorded |
| — | NCT07258628 | Oct 2025 → Jan 2026 | cardiac rhythm disease, hypertensive disorder | Ankara City Hospital Bilkent | Completed | No outcome recorded |
| — | NCT07310524 | Sep → Nov 2025 | — | Muhammad Rahman Efendi Nasution | Completed | No outcome recorded |
| — | NCT07166666 | Sep 2025 → Sep 2026 expected | — | Oman Medical Speciality Board | Not yet recruiting | No outcome recorded |
| — | NCT07114263 | Aug 2025 → Feb 2026 overdue | — | Tanta University | Not yet recruiting | No outcome recorded |
| — | NCT07062601 | Jul → Nov 2025 overdue | tonsillitis | Anqing Municipal Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06779968 | Jan → May 2025 overdue | — | Xiaguang Duan | Not yet recruiting | No outcome recorded |
| — | NCT07141589 | Aug 2024 → Nov 2025 overdue | — | Cairo University | Recruiting | No outcome recorded |
| Show all 116 trials opens the full record — a long page | ||||||
Also used as a comparator or background therapy in 727 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 015 trials | ||||||
| Phase 0 | NCT07711522 Background | Aug 2026 → Jul 2027 expected | — | Istanbul Medipol University Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07211399 Comparator | Jul 2026 → Dec 2030 | substance-related disorder | Jacques E. Chelly | Withdrawn | No outcome recorded |
| Phase 0 | NCT07040163 Comparator | Mar 2025 → Feb 2026 overdue | — | CAMC Health System | Active not recruiting | No outcome recorded |
| Phase 0 | NCT05824338 Comparator | Aug 2024 → Jul 2025 overdue | — | Fraser Health | Recruiting | No outcome recorded |
| Phase 0 | NCT07190625 Comparator | Dec 2023 → Mar 2026 overdue | — | Ain Shams University | Recruiting | No outcome recorded |
| Phase 0 | NCT06720285 Background | Oct → Nov 2023 | — | Universitas Airlangga | Completed | No outcome recorded |
| Phase 0 | NCT05539911 Comparator | Sep → Nov 2022 | — | Research Institute of Ophthalmology, Egypt | Unknown | No outcome recorded |
| Phase 0 | NCT05150795 Comparator | Jan 2022 → Dec 2026 expected | — | Ain Shams University | Recruiting | No outcome recorded |
| Phase 0 | NCT05051189 Comparator | Dec 2021 → Nov 2024 | obstructive sleep apnea syndrome | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 0 | NCT04648540 Comparator | Dec 2020 → Aug 2022 | — | Cairo University | Completed | No outcome recorded |
| Phase 0 | NCT04659642 Comparator | Nov 2020 → Mar 2021 | reactive airway disease, vascular hemostatic disease | National Cancer Institute, Egypt | Unknown | No outcome recorded |
| Phase 0 | NCT04230681 Comparator | Feb 2020 → Apr 2022 | obstructive sleep apnea syndrome, tonsillitis | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 0 | NCT03062488 Comparator | Oct 2017 → Jul 2018 | — | Nemours Children's Clinic | Completed | No outcome recorded |
| Phase 0 | NCT03088306 Comparator | Jul 2017 → May 2018 | lumbar disk degenerative disorder, lumbar spinal stenosis | Johns Hopkins University | Completed | No outcome recorded |
| Phase 0 | NCT02786329 Background | Jun 2016 → Aug 2022 | colorectal cancer | Regional Institute of Gastroenterology and Hepatology Prof. Dr. Octavian Fodor | Unknown | No outcome recorded |
| Phase 122 trials | ||||||
| Phase 1 | NCT07332130 Comparator | Dec 2025 → Jan 2026 overdue | — | Minia University Hospital | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06917898 Comparator | Apr 2025 → Apr 2026 overdue | — | Makassed General Hospital | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06318546 Comparator | Apr → Aug 2024 | benign shuddering attacks | Ain Shams University | Completed | No outcome recorded |
| Phase 1 | NCT06834854 Comparator | Mar → Aug 2024 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 1 | NCT06951230 Comparator | Feb → Aug 2024 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 1 | NCT06502262 Comparator | Jan → Aug 2024 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 1 | NCT05314569 Comparator | Apr → Sep 2022 | — | Cairo University | Completed | No outcome recorded |
| Phase 1 | NCT05402189 Comparator | Feb → Jun 2022 | — | Ain Shams University | Unknown | No outcome recorded |
| Phase 1 | NCT04955236 Comparator | Jul → Nov 2021 | infratentorial neoplasm | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 1 | NCT04941040 Comparator | Jul → Oct 2021 | supratentorial cancer | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 1 | NCT04221568 Background | Mar 2020 → Mar 2021 | — | Assiut University | Unknown | No outcome recorded |
| Phase 1 | NCT03938857 Comparator | Jul 2019 → Oct 2020 | — | Duke University | Terminated | No outcome recorded |
| Phase 1 | NCT03718507 Comparator | May → Dec 2019 | newborn respiratory distress syndrome | ASST Fatebenefratelli Sacco | Withdrawn | No outcome recorded |
| Phase 1 | NCT06867068 Comparator | Oct 2016 → Jun 2024 | — | Albert Einstein College of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT02014714 Comparator | Dec 2013 → Jun 2014 | obstructive sleep apnea syndrome | University of Malaya | Unknown | No outcome recorded |
| Phase 1 | NCT01668849 Comparator | Aug 2012 → May 2022 | chemotherapy-induced oral mucositis, head and neck cancer | University of Louisville | Completed | No outcome recorded |
| Phase 1 | NCT01210066 Comparator | Jul 2010 → May 2012 | — | University of California, Los Angeles | Terminated | No outcome recorded |
| Phase 1 | NCT01311778 Background | Feb 2010 → Oct 2011 | opiate dependence | Hurd,Yasmin, Ph.D. | Completed | No outcome recorded |
| Phase 1 | NCT00779467 Comparator | Oct 2008 → Nov 2013 | — | Wake Forest University | Completed | No outcome recorded |
| Phase 1 | NCT01607996 Comparator | Jul 2005 → Aug 2010 | acute pancreatitis | University Hospital, Geneva | Completed | No outcome recorded |
| Phase 1 | NCT00728832 Background | May 2002 → Feb 2003 | — | EKR Therapeutics, Inc | Completed | No outcome recorded |
| Phase 1 | NCT00709254 Comparator | Dec 2001 → Jan 2002 | — | YM BioSciences | Completed | No outcome recorded |
| Phase 1/211 trials | ||||||
| Phase 1/2 | NCT07443254 Background | Mar 2026 → Apr 2027 expected | — | CAMC Health System | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07034950 Comparator | Jun 2025 → Jun 2028 expected | liver cancer | The First Affiliated Hospital of Xiamen University | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06126991 Background | Jan → Dec 2024 | — | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT04686448 Comparator | Jan → Apr 2021 | — | Zagazig University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03903367 Comparator | May → Dec 2019 | — | Beni-Suef University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03778671 Comparator | Jan → Nov 2019 | — | Assiut University | Completed | No outcome recorded |
| Phase 1/2 | NCT03195309 Comparator | Jan 2017 → Dec 2018 | — | Kaohsiung Medical University Chung-Ho Memorial Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT01975753 Comparator | May 2014 → May 2018 | — | University Hospital, Rouen | Completed | No outcome recorded |
| Phase 1/2 | NCT02065947 Comparator | Oct 2013 → Mar 2014 | — | Ramathibodi Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT01425658 Comparator | Aug 2011 → Jan 2012 | — | Qazvin University Of Medical Sciences | Completed | No outcome recorded |
| Phase 1/2 | NCT01205997 Comparator | Aug → Dec 2010 | — | Qazvin University Of Medical Sciences | Completed | No outcome recorded |
| Phase 247 trials | ||||||
| Phase 2 | NCT07588802 Comparator | Jul 2026 → Apr 2027 expected | — | Massachusetts General Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07459166 Comparator | May → Jul 2026 overdue | acute opioid poisoning | Clear Scientific, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT07443085 Comparator | Feb 2026 → Jul 2027 expected | delirium | Benha University | Recruiting | No outcome recorded |
| Phase 2 | NCT07510217 Comparator | Aug 2024 → Dec 2025 | — | Tanta University | Completed | No outcome recorded |
| Phase 2 | NCT06326944 Comparator | Apr → Sep 2024 | — | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 2 | NCT06417268 Comparator | Mar 2024 → Sep 2025 | — | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 2 | NCT07368114 Comparator | Dec 2023 → May 2025 | — | Suez Canal University | Completed | No outcome recorded |
| Phase 2 | NCT06034873 Comparator | Nov 2023 → Sep 2025 | — | Benha University | Completed | No outcome recorded |
| Phase 2 | NCT06017141 Background | May 2023 → May 2025 | colon adenocarcinoma | University of Kansas Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT05487196 Comparator | Sep 2022 → Jul 2023 | pregnancy disorder | Grace Lim, MD, MS | Completed | No outcome recorded |
| Phase 2 | NCT05244226 Comparator | Apr 2022 → May 2023 | obstructive sleep apnea syndrome, tonsillitis | Duke University | Completed | No outcome recorded |
| Phase 2 | NCT04867343 Comparator | Jun 2021 → Aug 2023 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04899388 Comparator | Jun → Dec 2021 | — | Zagazig University | Completed | No outcome recorded |
| Phase 2 | NCT04410588 Comparator | Jun 2020 → Jul 2021 | — | Assiut University | Unknown | No outcome recorded |
| Phase 2 | NCT03993314 Comparator | Aug 2019 → Dec 2020 | pregnancy disorder | University of Alabama at Birmingham | Terminated | No outcome recorded |
| Phase 2 | NCT03968146 Background | Jun → Nov 2019 | idiopathic scoliosis | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03885596 Background | Mar → Jul 2019 | — | Concentric Analgesics | Completed | No outcome recorded |
| Phase 2 | NCT03854812 Comparator | Mar → Oct 2019 | — | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03908944 Comparator | Jan 2019 → Jan 2021 | — | Steven Edelstein | Withdrawn | No outcome recorded |
| Phase 2 | NCT03789318 Comparator | Dec 2018 → May 2019 | — | Concentric Analgesics | Completed | No outcome recorded |
| Phase 2 | NCT03979469 Comparator | Aug 2018 → Aug 2019 | — | Athens General Children's Hospital "Pan. & Aglaia Kyriakou" | Completed | No outcome recorded |
| Phase 2 | NCT03383588 Comparator | Jul → Aug 2018 | myofascial pain syndrome | Montefiore Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT03448068 Background | Apr 2018 → Jan 2020 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT03548493 Comparator | Apr → Aug 2018 | — | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03461718 Comparator | Mar 2018 → Oct 2019 | — | Brooke Army Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT03348423 Comparator | Nov 2017 → Jan 2018 | — | Baudax Bio | Completed | No outcome recorded |
| Phase 2 | NCT03084536 Comparator | Jun 2017 → Feb 2021 | female breast carcinoma | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT04541719 Comparator | Apr 2017 → May 2018 | — | Mansoura University | Withdrawn | No outcome recorded |
| Phase 2 | NCT03015857 Comparator | Jan → Mar 2017 | — | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02861716 Comparator | Aug 2016 → Feb 2019 | childhood malignant neoplasm | South Egypt Cancer Institute | Unknown | No outcome recorded |
| Phase 2 | NCT02877238 Comparator | Aug 2016 → May 2017 | congenital heart disease | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT05324891 Comparator | Jan 2016 → Aug 2017 | — | Mansoura University | Completed | No outcome recorded |
| Phase 2 | NCT02521415 Comparator | Dec 2015 → Nov 2016 | disease of bone structure | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01932554 Background | Nov 2013 → Mar 2015 | sickle cell disease | St. Louis University | Withdrawn | No outcome recorded |
| Phase 2 | NCT01937767 Background | Aug 2013 → Feb 2014 | — | Paion UK Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01896960 Comparator | Jul 2013 → Jun 2015 | hypotensive disorder, pregnancy disorder | McGill University Health Centre/Research Institute of the McGill University Health Centre | Unknown | No outcome recorded |
| Phase 2 | NCT02997800 Comparator | Nov 2012 → Jan 2019 | hypertensive disorder | Dr. Robert Tanzola | Completed | No outcome recorded |
| Phase 2 | NCT01703351 Comparator | Oct 2012 → Nov 2015 | lung neoplasm | Yonsei University | Completed | No outcome recorded |
| Phase 2 | NCT01794533 Comparator | Oct 2012 → Jan 2013 | pulpitis | Islamic Azad University, Sanandaj | Completed | No outcome recorded |
| Phase 2 | NCT01571791 Comparator | Jun 2012 → Dec 2021 | heart valve disorder | Mansoura University | Suspended | No outcome recorded |
| Phase 2 | NCT01516684 Background | May 2012 → Jun 2018 | cancer | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01845441 Comparator | Apr 2012 → Dec 2021 | brain ischemia, intracranial vasospasm, stroke disorder | University Hospitals Cleveland Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT01007773 Comparator | Jan 2010 → Jan 2011 | traumatic brain injury | University of Maryland, Baltimore | Withdrawn | No outcome recorded |
| Phase 2 | NCT00652028 Background | Nov 2008 → Apr 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00848393 Comparator | Nov 2008 → Dec 2013 | atrioventricular septal defect, tetralogy of fallot, ventricular septal defect | Nationwide Children's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01838707 Comparator | Dec 2007 → Mar 2013 | — | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT00390871 Comparator | May 2005 → Dec 2007 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2/320 trials | ||||||
| Phase 2/3 | NCT06382831 Comparator | Jun → Aug 2024 | — | Indonesia University | Unknown | No outcome recorded |
| Phase 2/3 | NCT07241351 Comparator | Mar → Nov 2024 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 2/3 | NCT07148882 Comparator | Feb → Sep 2024 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 2/3 | NCT05693675 Background | Oct 2023 → Jul 2024 | — | The University of Texas Health Science Center, Houston | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT06394375 Comparator | Jul → Oct 2023 | — | Indonesia University | Completed | No outcome recorded |
| Phase 2/3 | NCT04393610 Comparator | May → Aug 2020 | — | Assiut University | Unknown | No outcome recorded |
| Phase 2/3 | NCT03592537 Comparator | Aug 2018 → Apr 2021 | — | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT03143933 Comparator | Jul 2016 → Jul 2017 | — | Cairo University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02713191 Background | Mar 2016 → Feb 2017 | — | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| Phase 2/3 | NCT03000413 Comparator | Jun 2015 → Jun 2017 | asthma | Hospital Nossa Senhora da Conceicao | Completed | No outcome recorded |
| Phase 2/3 | NCT02752308 Comparator | Sep 2014 → Mar 2015 | hypospadias | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT01851720 Comparator | Jul 2012 → Sep 2014 | subarachnoid hemorrhage | Johns Hopkins University | Terminated | No outcome recorded |
| Phase 2/3 | NCT01508455 Background | Mar → May 2012 | — | Pfizer | Completed | No outcome recorded |
| Phase 2/3 | NCT02030717 Comparator | Feb 2012 → May 2015 | renal cell carcinoma | Umeå University | Completed | No outcome recorded |
| Phase 2/3 | NCT02203175 Comparator | Apr 2011 → Apr 2012 | — | Yeditepe University Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT01188551 Comparator | Jan 2011 → Apr 2012 | chronic otitis media | Nationwide Children's Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT01159262 Background | Jul 2010 → Aug 2011 | — | Pfizer | Completed | No outcome recorded |
| Phase 2/3 | NCT01558713 Comparator | Jan 2010 → Sep 2012 | neonatal compartment syndrome | University of Patras | Unknown | No outcome recorded |
| Phase 2/3 | NCT01582607 Comparator | Jan 2010 → Apr 2012 | neonatal compartment syndrome | University of Patras | Unknown | No outcome recorded |
| Phase 2/3 | NCT00644787 Comparator | Dec 2007 → Oct 2008 | cancer | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 362 trials | ||||||
| Phase 3 | NCT07565870 Comparator | Jul → Dec 2026 expected | — | Alexandre P. Joosten | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07299630 Background | Dec 2025 → May 2026 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT07120763 Comparator | Aug 2025 → Aug 2026 overdue | — | State University of New York at Buffalo | Recruiting | No outcome recorded |
| Phase 3 | NCT07165262 Comparator | Aug 2025 → Mar 2027 expected | brain neoplasm, epilepsy | Children's Cancer Hospital Egypt 57357 | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06873906 Comparator | Mar 2025 → Mar 2026 overdue | heart septal defect | Ain Shams University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07350668 Comparator | Jan 2025 → Jan 2026 | — | Benha University | Completed | No outcome recorded |
| Phase 3 | NCT06165679 Background | Dec 2023 → Jun 2025 | — | Cairo University | Completed | No outcome recorded |
| Phase 3 | NCT05437575 Comparator | Nov 2023 → Jul 2028 expected | — | Jason Sperry | Recruiting | No outcome recorded |
| Phase 3 | NCT06386783 Comparator | Jul 2023 → Jul 2024 | — | Aswan University | Unknown | No outcome recorded |
| Phase 3 | NCT05726968 Comparator | Nov 2022 → Jun 2023 | — | Cairo University | Completed | No outcome recorded |
| Phase 3 | NCT05887258 Comparator | May 2022 → May 2024 | — | Unai Ortega Mera | Completed | No outcome recorded |
| Phase 3 | NCT05444751 Comparator | Mar 2022 → Sep 2026 expected | lumbar disk disease, radiculopathy | Hospital for Special Surgery, New York | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT05099055 Comparator | Mar 2022 → Jan 2023 | — | St. Justine's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT05868200 Comparator | Feb → May 2022 | gingivitis | University of Baghdad | Completed | No outcome recorded |
| Phase 3 | NCT05165992 Comparator | Feb → Nov 2022 | pneumonia | Hamad Medical Corporation | Unknown | No outcome recorded |
| Phase 3 | NCT05958589 Background | Jan 2022 → Jul 2024 | — | University of Novi Sad | Completed | No outcome recorded |
| Phase 3 | NCT05641909 Comparator | Aug 2021 → Dec 2022 | — | Southeast University, China | Unknown | No outcome recorded |
| Phase 3 | NCT05003570 Comparator | Jun 2021 → Dec 2022 | — | Southeast University, China | Unknown | No outcome recorded |
| Phase 3 | NCT04908345 Comparator | May 2021 → Jan 2022 | chronic renal failure syndrome | University of Sao Paulo General Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04679818 Comparator | Dec 2020 → Dec 2022 | — | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 3 | NCT04355962 Comparator | Apr 2020 → Jun 2021 | COVID-19, acute respiratory distress syndrome | University of Zurich | Completed | No outcome recorded |
| Phase 3 | NCT04197570 Comparator | Feb → Mar 2020 | substance-related disorder | Benaroya Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT04081545 Comparator | Dec 2019 → Mar 2023 | substance-related disorder | Christine Oryhan | Completed | No outcome recorded |
| Phase 3 | NCT06185127 Comparator | Sep 2019 → May 2020 | lung disorder | University of Patras | Completed | No outcome recorded |
| Phase 3 | NCT03751423 Comparator | Jun 2019 → Dec 2023 | — | Dr. Marie Eve Sophie Bussiere-Cote | Suspended | No outcome recorded |
| Phase 3 | NCT03762343 Comparator | Jan 2019 → Dec 2020 | infratentorial neoplasm | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 3 | NCT03434678 Background | Jan 2018 → Jul 2024 | malignant pancreatic neoplasm | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT02987985 Comparator | Oct 2017 → Sep 2019 | obstructive sleep apnea syndrome, respiratory underresponsiveness to hypoxia and hypercapnia | University of Saskatchewan | Completed | No outcome recorded |
| Phase 3 | NCT03669484 Background | Aug 2017 → May 2018 | — | R-Pharm | Completed | No outcome recorded |
| Phase 3 | NCT04414800 Comparator | Apr 2017 → Mar 2018 | — | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT03018756 Comparator | Jan 2017 → Jun 2018 | interstitial lung disease | Dr. Denis O'Donnell | Completed | No outcome recorded |
| Phase 3 | NCT04762147 Comparator | Oct 2016 → Jun 2017 | — | Aga Khan University | Completed | No outcome recorded |
| Phase 3 | NCT02841488 Comparator | Sep 2016 → Sep 2018 | peripheral arterial occlusive disease 1 | University of Sao Paulo General Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02752477 Comparator | Aug 2016 → Sep 2020 | chronic pain syndrome | Ben Lim | Unknown | No outcome recorded |
| Phase 3 | NCT03110003 Comparator | Jun 2016 → Dec 2017 | — | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 3 | NCT02778880 Comparator | Mar 2016 → Feb 2017 | — | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 3 | NCT02880540 Comparator | Mar 2016 → Feb 2018 | obesity disorder | Janelle Vaughns | Completed | No outcome recorded |
| Phase 3 | NCT02634255 Background | Dec 2015 → May 2016 | appendicitis | Diskapi Yildirim Beyazit Education and Research Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02533908 Comparator | Sep 2015 → Oct 2017 | poisoning | University Children's Hospital, Zurich | Completed | No outcome recorded |
| Phase 3 | NCT02480114 Background | Jul 2015 → Sep 2019 | head and neck cancer, mucositis, radiation-induced disorder | Vanderbilt-Ingram Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT02466022 Background | Jun → Nov 2015 | — | University of Saskatchewan | Completed | No outcome recorded |
| Phase 3 | NCT02278601 Background | Jan 2015 → May 2019 overdue | — | KK Women's and Children's Hospital | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02150161 Comparator | May 2014 → Aug 2015 | — | Clinica Santa Maria | Terminated | No outcome recorded |
| Phase 3 | NCT02444897 Comparator | Sep 2013 → Dec 2014 | gastric cancer | Keimyung University Dongsan Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT01794247 Comparator | Apr → Dec 2013 | — | Hospital General de Ciudad Real | Terminated | No outcome recorded |
| Phase 3 | NCT02658721 Background | Jan → Jun 2013 | — | Bagcilar Training and Research Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01768377 Comparator | Nov 2012 → Feb 2013 | — | Tehran University of Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT01724983 Comparator | Jun 2012 → Jun 2014 | morbid obesity | University of Padova | Unknown | No outcome recorded |
| Phase 3 | NCT00875550 Comparator | Jan 2010 → Jan 2011 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00871442 Comparator | May 2009 → Mar 2010 | — | Neil Roy Connelly, MD | Withdrawn | No outcome recorded |
| Phase 3 | NCT00848419 Comparator | Apr → Dec 2009 | — | Hadassah Medical Organization | Withdrawn | No outcome recorded |
| Phase 3 | NCT01858090 Comparator | Jan → Oct 2009 | — | Baskent University | Completed | No outcome recorded |
| Phase 3 | NCT00926705 Comparator | Jun 2008 → Jan 2009 | — | University of Jordan | Completed | No outcome recorded |
| Phase 3 | NCT00647127 Comparator | Feb 2008 → Aug 2009 | — | University of Aarhus | Completed | No outcome recorded |
| Phase 3 | NCT00571636 Comparator | Dec 2007 → Apr 2010 | neonatal respiratory failure, perinatal disease | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Completed | No outcome recorded |
| Phase 3 | NCT00542542 Comparator | Sep 2007 → Mar 2014 | breast cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT00589823 Comparator | Jun 2007 → Mar 2009 | neuropathy, painful | Archimedes Development Ltd | Completed | No outcome recorded |
| Phase 3 | NCT00468052 Comparator | Mar 2007 → May 2008 | obstructive sleep apnea syndrome | University of Medicine and Dentistry of New Jersey | Completed | No outcome recorded |
| Phase 3 | NCT00419601 Comparator | Nov 2006 → Apr 2010 | — | University of Cologne | Completed | No outcome recorded |
| Phase 3 | NCT00713726 Comparator | Jan 2006 → Jul 2008 | — | Federal University of São Paulo | Completed | No outcome recorded |
| Phase 3 | NCT00286143 Comparator | Feb 2005 → Dec 2007 | congenital pulmonary airway malformation | Children's Hospital of Philadelphia | Completed | No outcome recorded |
| Phase 3 | NCT00187135 Comparator | Mar 2002 → Aug 2008 | bone marrow disorder | St. Jude Children's Research Hospital | Terminated | No outcome recorded |
| Phase 4254 trials | ||||||
| Phase 4 | NCT07637279 Comparator | Nov 2026 → Jun 2028 expected | polyp of large intestine | Karolinska Institutet | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07650552 Comparator | Sep 2026 → Aug 2028 expected | apnea of prematurity, newborn respiratory distress syndrome, pulmonary immaturity | UEA - Universidade Do Estado Do Amazonas | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07697404 Background | Jun 2026 → Jul 2028 expected | — | Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| Phase 4 | NCT07560501 Comparator | Apr → Dec 2026 expected | — | Tribhuvan University Teaching Hospital, Institute Of Medicine. | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07334132 Background | Apr 2026 → Dec 2029 expected | osteoarthritis | Region Örebro County | Not yet recruiting | No outcome recorded |
| Show all 254 trials opens the full record — a long page | ||||||
| Phase not applicable296 trials | ||||||
| — | NCT07680400 Comparator | Jul → Aug 2026 overdue | — | Bezmialem Vakif University | Not yet recruiting | No outcome recorded |
| — | NCT07640516 Comparator | Jul 2026 → Jan 2027 expected | — | Kasr El Aini Hospital | Recruiting | No outcome recorded |
| — | NCT07658521 Background | Jul → Dec 2026 expected | — | Ain Shams University | Enrolling by invitation | No outcome recorded |
| — | NCT07636070 Comparator | Jun → Aug 2026 overdue | urolithiasis | murat sahin | Not yet recruiting | No outcome recorded |
| — | NCT07558226 Comparator | May 2026 → Nov 2027 expected | — | Fundacio Puigvert | Recruiting | No outcome recorded |
| Show all 296 trials opens the full record — a long page | ||||||
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2008-10-20 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces FDA Approval and Commercial Launch of Fentanyl Transdermal System tevapharm.com ↗ |
Evidence & citations 129 cited values
Every value below carries the sentence it was read from. 1,131 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fentanyl | “The current double-blind, placebo-controlled in-patient study was designed to compare the effects of intravenously delivered fentanyl (0, 0.0625, 0.125, 0.187, and 0.250 mg/70...” PMID 17581533 ↗ Jun 20071093“patients whose labor analgesia is maintained using PIEB with low-volume bolus (6.25 mL) of a higher local anesthetic concentration solution (0.1% bupivacaine with fentanyl 2.0...” NCT03553576 ↗ “After the surgery: 10 ml 0.25% bupivacaine through epidural catheters before extubation and continuous infusion of 0,1% bupivacaine and 1 µg/ml fentanyl 5 ml/h with...” NCT02622893 ↗ “Participants will be induced using lidocaine 1 mg/kg IV, an opioid such a fentanyl (1-2 mcg/kg) IV, followed by 0.6 mg/kg IV rocuronium, and IV propofol with dosage at the...” NCT06029049 ↗ “The parturients were randomly assigned to groups receiving either spinal sufentanil (5 µg), epidural sufentanil (20 µg), spinal fentanyl (20 µg) or epidural fentanyl (100 µg),...” PMID 31286476 ↗ Jul 2019 “Preservative free 0.5% Hyperbaric bupivacaine (AstraZeneca) 5mg + 25mcg fentanyl for the initial dose will be followed by top up doses of 2.5 mg boluses of 0.5% Hyperbaric...” NCT05897151 ↗ “Maintenance of anesthesia will be achieved by isoflurane at an end tidal concentration of 1-1.5% in FiO2 of 0.5, intravenous fentanyl at a dose of 1 µg/kg in incremental...” NCT06873906 ↗ “Intraoperative analgesia will be ensured by administering fentanyl 0.5-1 µg/kg as needed, based on clinical signs of inadequate analgesia (e.g., an increase in blood pressure...” NCT07207304 ↗ “Intraoperatively, fentanyl in fractional doses of 1-3 µg∙kg-1 were applied if the heart rate (HR; Heart Rate) or mean blood pressure (MBP; Mean Blood Pressure) increased by...” NCT04355468 ↗ “The administered anesthetic mixture will include a fixed dose of fentanyl (15 μg), a variable dose of ropivacaine based on the parturient's somatometric characteristics, and a...” NCT07023497 ↗ “The patient will be sedated with a combination of midazolam, fentanyl administered intravenously in small boluses until the desired level of sedation is achieved as expressed...” NCT03546088 ↗ “1-3 mg IV propofol 0.5 mg/kg IV Rocuronium + Fentanyl 2-3 mcg/kg + Morphine 0.1mg/kg IV Maintenance: Volatile anesthetic + High volume local anesthesia infiltration Bupivacaine...” NCT03176758 ↗ “BioDelivery Sciences International, Inc. (BDSI) has developed BioErodible MucoAdhesive (BEMA) Fentanyl, an alternative product to OTFC that does not require the subject to...” NCT00293033 ↗ “Induction of anesthesia will be the same for all patients and consist of intravenous anesthetic propofol (2-3 mg/kg), opioid analgesic fentanyl (1-1.5 mcg/kg), and muscle...” NCT05958589 ↗ “This study evaluated the long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet (sublingual fentanyl ODT), for the treatment of BTcP in...” PMID 21208151 ↗ Jan 2011 “A patient-controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol including a 10 mcg bolus without an infusion dose, a 10-minute...” NCT07278050 ↗ “Fentanyl group recieve induction and maintenance doses of fentanyl by target controlled infusion in addition of propofol-dexmedetomidine as total intravenous anesthesia for...” NCT06031883 ↗ “Intraoperative analgesia using short-acting opioids (e.g., fentanyl and/or hydromorphone) administered at induction and throughout surgery according to clinician judgment and...” NCT07565870 ↗ “This typically involves the intravenous (IV) administration of strong opioids such as Fentanyl or Sufentanil to manage the intense pain during the craniotomy (bone flap...” NCT07510217 ↗ “A patient-controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol including 10 mcg bolus without infusion dose, 10 min lockout...” NCT05972122 ↗ “A patient-controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol including 10 mcg bolus without infusion dose, 10 min lockout...” NCT06546839 ↗ “Fentanyl IV infusion via PCA (patient controlled analgesia) machine of fentanyl 10 μg/ml, ramosetron 0.3 mg, normal saline, total 100 ml, infusion rate 1 ml/hr, 1 ml bolus and...” NCT04061057 ↗ “JNS020QD is a transdermal system in which fentanyl base is incorporated directly into a single layer of pressure-sensitive high polymerized adhesive, and is changed once a day...” NCT01493245 ↗ “Standard of Care analgosedation of choice using propofol, fentanyl, dexmedetomidine, morphine, hydromorphone, midazolam, or lorazepam administered according to the...” NCT06429657 ↗ “In the EVE group, 1 mL of a mixture containing a combination of 10 µg fentanyl and 0.25% isobaric bupivacaine was injected into the intrathecal region via a 25-G 120 mm...” PMID 40068075 ↗ Mar 2025 “This trial evaluated the efficacy and long-term tolerability of a sublingual formulation of the fast-acting opioid fentanyl, for the treatment of BTcP in opioid-tolerant...” PMID 19814586 ↗ Dec 2009 “Patients in control group will receive a conventional GA with fentanyl 2µg/kg given during induction of anesthesia and one fourth of initial dose of fentanyl will be given over...” NCT07213687 ↗ “Fentanyl 25 mcg intravenous push (IVP) every 5 min up to 4 doses hourly as needed to target pain score for the study design duration (28 days) or for the duration of mechanical...” NCT02219659 ↗ “Patients in the TIVA group had anesthesia induced with propofol 2 mg/kg , fentanyl 1 ug/kg and maintained with propofol. 200 ug/kg/min, fentanyl 0.1ug/kg/min, dexmedetomidine 1...” NCT06423846 ↗ “One patch of SyB P-1501 contains 10.8 mg of fentanyl hydrochloride (fentanyl 9.7 mg) and produces an electric current to deliver the drug iontophoretically after the system is...” NCT03005899 ↗ “Intravenous moderate sedation (fentanyl 100 mcg and midazolam 2 mg) versus oral analgesia/anxiolysis (lorazepam 2 mg sublingual, hydrocodone/acetaminophen 5/500 mg, and...” NCT01011634 ↗ “In the Remifentanil group, patients will be administered in a total volume of 20 mL, 2 mcg/kg of fentanyl. As maintenance, they will be receiving 1 mL/10kg/h of a remifentanil solution” NCT05717361 ↗ “In addition to propofol as a hypnotic and rocuronium as a muscle relaxant, patients in the conventional opioid-based group will receive the following drugs: Remifentanil and Fentanyl” NCT05485480 ↗ “Fentanyl 2mcg/kg only at induction and infusion of propofol and remifentanil for maintenance, with doses adjusted according to bispectral index indication ( BIS maintained 40-60).” NCT04976842 ↗ “This study aimed to investigate the effect of the equivalent doses of fentanyl, oxycodone, and butorphanol on bowel function in patients undergoing laparoscopic hysterectomy.” PMID 35209847 ↗ Feb 2022 “General anesthesia will be induced with fentanyl 1,5 mcg/kg, propofol 2 mg/kg, rocuronium 0,6 mg/kg; after intubation anesthesia will be mantained with sevoflurane (MAC 1).” NCT04294537 ↗ “General anesthesia: induction of general anesthesia to facilitate endotracheal intubation: fentanyl (up to 2μg.kg.min-1), propofol (1-2 mg.kg-1), vecuronium (1-2 mg.kg-1).” NCT05444751 ↗ “general anesthetic by midazolam 0.02 mg kg-1 , propofol 2-3 mg kg-1 and lidocaine 0.5 mg kg-1 , fentanyl 2 μg kg-1 , atracurium 0.5 mg kg-1 , isoflurane in 50% oxygen/air.” NCT03569046 ↗ “Injection of 100 mcg of morphine, 15 mcg of fentanyl and 0.25 ml of normal salin (sterile) with 12 mg of bupivacaine in the intrathecal space to provide spinal anesthesia.” NCT05099055 ↗ “Standard thoracic epidural analgesia mixture (2 mg/ ml bupivacaine, 2 µg/ ml fentanyl and 2 µg/ ml adrenalin) with an infusion of 6-10 ml/hour until day 2 postoperatively.” NCT04025606 ↗ “Induction of anaesthesia: fentanyl 1 μg.Kg-1, propofol 1.5-2 mg.kg -1 titrated to loss of verbal response, atracurium 0.5 mg. Kg-1 to facilitate endotracheal intubation.” NCT04095754 ↗ “with fentanyl, (1mcg / kg), propofol (1-2 mg / kg), atracurium (0.5 mg / kg), intubation. Anesthesia maintained using Propofol (4-6) mg/kg/h, fentanyl (0.5-1) μg/kg/h.” NCT03437213 ↗ “Compare the opioid based anesthesia with Fentanyl and Remifentanyl to opioid free anesthesia with dexmedetomidine and lidocaine and their effect on postoperative pain.” NCT03417193 ↗ “Total IntraVenous Anesthesia - to achieve deep-sedation via chemical analgesic (propofol, dexmedetomidine, fentanyl, hydromorphone); continuous intravenous infusion.” NCT07672301 ↗ “Propofol 1,5mg/Kg, supplemented by fentanyl 2mcg/Kg and rocuronium 0,5mg/Kg and O2 100% will be for induction to anesthesia and facilitate endotracheal intubation. .” NCT04802122 ↗ “using dexmedetomidine, propofol and fentanyl as total intravenous anaesthestics (TIVA) in comparison with sevoflurane - fentanyl anesthesia in brain tumor resection.” NCT02575521 ↗ “both midazolam (0.05 mg/kg body weight; 1 mg if age \> 70 or ASA class III-IV) and fentanyl (50 µg; 25 µg if age \> 70 or ASA class III-IV) were given intravenously” NCT01321047 ↗ “In this group patient will receive intrathecal hyperbaric bupivacaine based on patients height and weight according to Harten chart with 10 μg of fentanyl (0.1 ml)” NCT04082676 ↗ “may use a combination of fentanyl, midazolam, dexmedetomidine infusion (with or without loading dose), and/or low-dose propofol by intermittent bolus or infusion” NCT03263117 ↗ “Droperidol 1.25 mg and fentanyl 0.025 mg (diluted with normal saline up to 5ml) is to be administrated intravenously 30 minutes before the end of the procedure.” NCT05068180 ↗ “Induction agents will be administered as quick boluses (Propofol 2,5mg/kg total body weight, max 350mg, Fentanyl 250mcg, Rocuronium 1,2mg/kg ideal body weight).” NCT03239236 ↗ “PACU analgesia for both groups will be the usual care regime of fentanyl or hydromorphone bolus as prescribed by the physician anesthesiologist doing the case.” NCT05693675 ↗ “i.e., a programmed intermittent bolus of 10 ml of 0.1% bupivacaine and 2 μg/ml fentanyl every hour until the completion of labor and suturing of the incision.” NCT06580327 ↗ “Post-procedure analgesia in both groups was provided via IV fentanyl 0.5-1 µg/kg, administered as needed for patients reporting an NRS score greater than 4.” NCT07303309 ↗ “Anesthetic agents, including propofol, fentanyl, rocuronium, and sevoflurane, were used as part of standard anesthetic management during the procedure.” NCT07370779 ↗ “The participants will receive intravenous midazolam, propofol or fentanyl with topical proparacaine and sub-tenon's mixture of lidocaine and marcaine.” NCT04346095 ↗ “Induction with 1% propofol (2-3 mg/kg), fentanyl (1-3 mg/kg), and Rocuronium 1-1.5 mg/kg. Before the injection of propofol, 5 mL 1% lidocaine (50 mg)” NCT04281017 ↗ “Standardized general anaesthesia with fentanyl 2 mcg/kg ABW at induction, propofol 1.5 mg/kg, rocuronium 0.6 mg/kg, sevoflurane 1 MAC for maintenance” NCT07299630 ↗ “General anesthesia induction will be performed with fentanyl 1-2 μg/kg, propofol 2-3 mg/kg, and rocuronium 0.6 mg/kg and maintained with sevoflurane.” NCT06584695 ↗ “Patients were given 1.5 mcg/Kg of fentanyl intravenously. two minutes after the fentanyl dose, a dose of 1.5 mg/kg of propofol slowly over 2 minutes.” NCT04284644 ↗ “Local anesthesia (e.g., 2% Lidocaine) and conscious sedation (e.g., Fentanyl and Midazolam) will be administered to the patient during the procedure” NCT06426992 ↗ “Patients in all groups will be attached to IV PCA containing 10 mcg/ml fentanyl, 10 mcg bolus without infusion dose, and 10 min lock time protocol.” NCT05566561 ↗ “Epidural anesthesia placed at L1-L2 Epidural infusion of ropivacaine 0.2% + 3-4 mcg/ml fentanyl + saline 0.9% (100 ML) 3-5ml/ hr during 120 hours” NCT02617199 ↗ “Anesthesia will be maintained by total intravenous anesthesia with propofol infusion (4 to 12 mcg/kg/min) and fentanyl infusion (1-2mcg /kg/hour)” NCT06613893 ↗ “Patients will be subjected to total intravenous anesthesia with propofol-fentanyl+i.v. lidocaine infusion for the first 48 h postoperatively” NCT02786329 ↗ “Group FENT, consisting of 29 patients, underwent a saddle block with hyperbaric bupivacaine (2.5 ml) combined with fentanyl (0.5 ml; 25 μg).” NCT06216197 ↗ “patients will receive fentanyl 2 μg/kg loading dose which will be prepared over 20 ml syringe and infused over 10 minutes prior to induction” NCT04941040 ↗ “Optional intrathecal opioid adjuncts, with fentanyl or sufentanil, may be used to enhance analgesia according to routine clinical practice.” NCT07334132 ↗ “Induction of anesthesia will be done by injecting fentanyl 2 μg/kg, propofol1.5-2.5 mg/kg and atracurium 0.5 mg/kg for muscle relaxation.” NCT05632159 ↗ “Patients will receive continuous epidural analgesia using bupivacaine 0.125% in conjunction with fentanyl 2 ug/ml at a rate of 8-15 ml/hr” NCT04541719 ↗ “intrathecal 50 mg (2.5 ml) of prilocaine 2% (Takipril, prilocaine hydrochloride 20 mg/mL, hyperbar, Sintetica) + 25 ug fentanyl (0.5 ml).” NCT06133881 ↗ “Group M will be given a 0.5% Bupivacain Dosage Regimen with weight and height adjustment+15 μg fentanyl +150 μg morphine intrathecally.” NCT05405049 ↗ “Epidural medication will be the same in both groups and will consist of bupivacaine 0,05% with fentanyl 2 µg/mL and adrenaline 2 µg/mL.” NCT05534945 ↗ “epidural anesthesia: patients get an continuous infusion of a solution with bupivacain 1 mg/ml, fentanyl 1 ug/ml and adrenalin 1 ug/ml” NCT02030717 ↗ “Boluses of fentanyl 1 µg/kg actual body weight (ABW), up to a maximum dose of 100 µg per bolus, can be given per clinical judgement.” NCT04679818 ↗ “Intravenous sedation in control group will be continued as initiated at the ICU e.g. propofol, fentanyl, midazolam, dexmedetomidine” NCT04355962 ↗ “patients will be premedicated with the undiluted IV formulation of fentanyl citrate (50 µg/mL), 10 µg/kg up to 400 µg per patient.” NCT04991298 ↗ “Intra-operatively, opioids will be titrated to heart rate and spontaneous respiration rate e.g. fentanyl, morphine, hydromorphone.” NCT03471442 ↗ “Standard sedation: fentanyl 2x0,5 microg/kg at beginning of procedure and propofol PCS: 20mg bolus than 10mg/bolus, lock-out = 0.” NCT00913861 ↗ “1- Standard dose group: receiving the typical dose of hyperbaric bupivacaine (12.5 mg hyperbaric bupivacaine + 25 mcg fentanyl).” NCT07140640 ↗ “administer anesthesia based on opioids such as fentanyl and/or morphine to guarantee analgesia during the surgical intervention.” NCT05887258 ↗ “Fentanyl infusion (0.5 μg/kg/h) was started after induction and continued intraoperatively according to institutional protocol.” NCT07259057 ↗ “The unit's protocol includes drugs such as Morphine, Hydromorphone, Fentanyl, Clonidine, Ketamine, Midazolam and Acetaminophen.” NCT04538573 ↗ “Induction was carried out by fentanyl 3mcg/kg, propofol 2 mg/kg and rocuronium at the dose of 1mg/kg to facilitate intubation” NCT05417529 ↗ “Patient in this group will receive the intraoperative standard of care(intraoperative intravenous fentanyl and paracetamol)” NCT03762343 ↗ “Anaesthesia induction will be obtained with i.v. 2-3 mg/kg propofol, 0,6-0,8 mcg/kg fentanyl, and 0.9-1,2 mg/kg rocuronium.” NCT03157479 ↗ “Intravenous injection midazolam 0.05 mg/Kg,fentanyl 4μg/Kg,etomidate 0.2 mg/Kg,cisatracurium 0.15 mg/Kg in proper order.” NCT02289391 ↗ “Administer 7 μg/kg of fentanyl first,then given remimazolam 0.2 mg/kg (1-minute bolus), followed by 1 mg/kg/h infusion.” NCT07335536 ↗ “atracurium 0.5mg/kg to facilitate endotracheal intubation and fentanyl 1 mcg/kg ,Mechanical ventilation was adjusted” NCT04614259 ↗ “The ED95 of Ciprofol for Laryngeal Mask Airway Insertion With Fentanyl in Children: A Biased-Coin Dose-Finding Trial” NCT07697404 ↗ “Propofol 5-6 mg/kg and fentanyl 2 µg/kg for induction of anesthesia and propofol 250-300 µg/kg/min for maintenance” NCT03553082 ↗ “GA will be induced with midazolam 1-2 mg, fentanyl 2μ/kg and propofol titrated to achieve loss of consciousness.” NCT03013075 ↗ “using intraoperative opioids such as fentanyl or remifentanil, administered according to institutional protocols” NCT07310524 ↗ “Patients received inhalation induction using sevoflurane 8% and fentanyl 2 µg/kg was administered intravenously.” NCT05019560 ↗ “Intraoperative opioids (Fentanyl or Morphine) will be administered as deemed necessary by anesthesia care team.” NCT01500109 ↗ “Participants in the interventional group will receive an initial dose of 100 mcg IV fentanyl during induction.” NCT07614607 ↗ “general anesthesia induction with 1mcg/kg of IV Fentanyl, 2mg/kg of IV Propofol and 0.5 mg/kg of IV Atracurium” NCT06202664 ↗ “IV PCA (fentanyl 10mcg/kg + nefopam (Acupan®) 80mg + Ramosetron (Nasea®) ) apply 30min before end of surgery.” NCT03462836 ↗ “Patients will receive 150% of their oral morphine equivalent (OME) utilizing the drugs Dilaudid and Fentanyl.” NCT01447888 ↗ “Subarachnoid block will be performed using Bupivacaine hydrochloride (2.2 mL) in addition to fentanyl 25 mcg.” NCT03792906 ↗ “patients in group C will receive fentanyl 1 μg/kg, propofol 2.5 mg/kg, and rocuronium 0.3 mg/kg intravenously” NCT07680400 ↗ “All patients were induced with individual intravenous doses of midazolam, rocuronium, fentanyl and propofol.” NCT02399397 ↗ “The administered drugs, as outlined in the arms section, are midazolam, fentanyl, propofol, and sevoflurane.” NCT02058511 ↗ “Subarachnoid block will be performed using Bupivacaine hydrochloride (2.2 mL) in addition to fentanyl 25 mcg” NCT03712111 ↗ “Analgesia will be provided by fentanyl in induction and maintenance according to Ideal Body Weight (IBW)” NCT06343753 ↗ “10 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl injected to the epidural space” NCT03110003 ↗ “standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflurane” NCT01868425 ↗ “Prior to emergence, 100-200 mcg of fentanyl will be titrated for additional analgesia after emergence.” NCT03908944 ↗ “General anesthesia with Lidocaine 1.5mg/kg, Fentanyl 2 mcg/kg, propofol 2 mg/kg, Rocuronium 0.6 mg/kg” NCT06892600 ↗ “with 1 microgram/kilogram (mcg/kg) of fentanyl and 1.2 mg/kg rocuronium once IV access is established” NCT03408340 ↗ “Total intravenous anesthesia (propofol plus fentanyl) in addition to remote ischemic preconditioning” NCT02877238 ↗ “After intravenous (IV) placement, 1-3mg/kg of propofol and 1mcg/kg of fentanyl will be administered.” NCT03467750 ↗ “Patients in both groups will receive intravenous patient-controlled analgesia (PCA) using fentanyl.” NCT01833728 ↗ “Propofol 2-3mg/kg IV, Fentanyl 1mcg/kg IV, neuromuscular block w/succinylcholine and/or rocuronium” NCT03448068 ↗ “Anesthesia was maintained with isoflurane at a concentration of 2-2.5%. fentanyl 50 ug increments” NCT02739958 ↗ “The doses used of Levobupivacaine Hydrochloride 0.5% will be 6 mg and the dose of fentanyl 10 μg.” NCT03843970 ↗ “Intraoperative: fentanyl 5-10 mcg/kg at induction with supplemental 1-2 mcg/kg boluses as needed.” NCT07658521 ↗ “The anesthesiologist will administer 4 mL of ropivacaine 0.5% plus fentanyl 15 mcg intrathecally” NCT05824338 ↗ “Tetracaine 2mg will be combined with Fentanyl 20 mcg and Epinephrine 50 mcg to treat labor pain.” NCT01005459 ↗ “The patients will receive a single injection of spinal anesthesia using prilocaine plus fentanyl” NCT06165679 ↗ “rescue intravenous analgesia using 50 mcg of fentanyl will be administered by anaesthesiologist” NCT04500249 ↗ “Spinal anesthesia performed with 12,5mg of bupivacaine with 25mcg fentanyl for cesarean section” NCT03231436 ↗ “fentanyl 2 mcg/kg (bolus) and morphine given by PCA (patient-controlled analgesia) at 1 mg/dose” NCT05069311 ↗ “In the ED Rescue analgesic medication for all patients: Fentanyl 50mcg i.v. (max. 200mcg/hour)” NCT04685291 ↗ “A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients” NCT04189640 ↗ “A patient-controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients” NCT06866054 ↗ “Participants will receive usual care with IV Fentanyl or hydromorphone per hospital protocols” NCT06110546 ↗ “intranasal fentanyl (INF) is effective for rapidly decreasing MSK-I related pain in children” NCT02985177 ↗ “50 mcg of fentanyl citrate was given as a 15-minute intravenous infusion in 150 cc isotonic.” NCT05500677 ↗ “IV-PCA (fentanyl 10 mcg/ml) Dose bolus-lock out time - basal = 1.5 ml - 15 min - 1.5 ml/hr” NCT01269099 ↗ “to characterize the pharmacokinetics profile of ACTIQ (fentanyl citrate) in these children” NCT00236041 ↗ “All patients will receive a standarised dose of paracetamol 15mg/kg and fentanyl 2mcg/kg.” NCT03167047 ↗ “We thus determine appropriate dose of fentanyl (bolus dose and background infusion rate)” NCT01863355 ↗ “iv-PCA setting was fentanyl 20 mcg/ml, bolus/lock out time/basal, 0.5 ml/15 min/0.5 ml.” NCT02491385 ↗ “Traditional general anesthetic technique utilizing sufentanil, fentanyl or remifentanil” NCT02752477 ↗ “Anesthesia is induced with 1 µg/kg fentanyl, 1.5-2 mg/kg propofol and 1-2 mg midazolam.” NCT02534012 ↗ “in combination with Fentanyl (25µg) in day-case lower abdominal and urologic surgeries” NCT05726968 ↗ “8 mg hyperbaric bupivacaine with added 25 µg fentanyl to form a total volume of 2.1 ml” NCT03356899 ↗ “Patients will receive o.5 ug/kg/hr fentanyl infusion all through the whole operation.” NCT06984276 ↗ “patient control epidural analgeisa using 0.2% levobupivacaine with 2ug/ml fentanyl” NCT01158586 ↗ “Fentanyl was administered at a dose of 3 mcg/kg at 5 minutes of this application.” NCT06958913 ↗ “Patients will be anesthetized using Fentanyl (2 mcg/kg) and Propofol (1-2 mg/kg).” NCT04473846 ↗ “Patients received 0.5% bupivacaine hyperbaric (2.5 ml) + fentanyl 25 µg (0.5 ml).” NCT07664618 ↗ “They will receive 20 mg of 0.5% hyperbaric bupivacaine plus 25 microgram fentanyl” NCT06550180 ↗ “Hydromorphone or fentanyl will be used in patients who do not tolerate morphine.” NCT01932554 ↗ “1 microgram/kg Fentanyl, and 2 minutes later receive 1 mg/kg Propofol (Diprivan)” NCT02079090 ↗ “During general anesthesia, fentanyl is administered according to NOL monitoring.” NCT06070701 ↗ “Spinal anesthesia will be induced with isobaric 2% lidocaine and 15 μg fentanyl.” NCT02574832 ↗ “the EDA group had an epidural infusion of bupivacaine, adrenalin and fentanyl.” PMID 30837253 ↗ Mar 2019 “Patients in both groups received fentanyl 2 ug\\kg and atracurium 0.5 mg\\kg.” NCT04365686 ↗ “All patients will receive a spinal anesthetic using Fentanyl and Bupivacaine” NCT02197273 ↗ “The bolus will consist of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml.” NCT03735771 ↗ “3.0 ml of heavy levo-bupivacaine with10 µg fentanyl (0.5 ml) to make 3.5 ml” NCT06970574 ↗ “Induction by intravenous fentanyl (1.5 µg kg-1) and propofol (2.5 mg kg-1)” NCT02355678 ↗ “5 mg hyperbaric bupivacaine 0.5% and 25 mcg fentanyl for spinal anesthesia” NCT03834454 ↗ “propofol 2mg/kg , atracurium0.5ml/kg ,fentanyl 100 microgram in induction” NCT03422354 ↗ “Sedation will be administered using low-dose midazolam and/ or fentanyl.” NCT04887285 ↗ “initial bolus dose of fentanyl (fentanyl 50 mcg/ml, hameln; Netherlands)” NCT06464263 ↗ “Midazolam, Propofol, Fentanyl, Cisatracurium or alternatively Rocuronium” NCT05172739 ↗ “Fentanyl will be given, if needed, in doses of 0.25-0.5 mg intravenously” NCT07637279 ↗ “Prilocaine 40mg (2ml) + fentanyl 25mcg in unilateral spinal anesthesia” NCT07262398 ↗ “Fentanyl (Actiq®, Duragesic®, Fentora®, Lazanda®, Subsys®, and others)” NCT06240390 ↗ “Both groups will receive the same medications (propofol and fentanyl).” NCT07569016 ↗ “20 mcg of "Fentanyl," "Martindale pharma Fentanyl®," 50mcg/ml (0.4ml)” NCT06769737 ↗ “with intra-operative fast acting opioid analgesics, Fentanyl 2 mic/kg” NCT04238377 ↗ “patients will receive fentanyl (3-6 mcg/kg) at anesthesia induction.” NCT00413582 ↗ “using 10mg of 0.5% hyperbaric Bupivicaine and Fentanyl 20 micrograms” NCT02784340 ↗ “Fentanyl, an opioid, is strongly related to the development of PONV” PMID 38335521 ↗ Feb 2024 “Standard epidural placement. Ropivacaine 0.1% and Fentanyl 2mcg/mL.” NCT03074695 ↗ “ * Fentanyl * Benzodiazepine and / or anti-psychotic for agitation” NCT02009306 ↗ “1 ml 0.5% isobaric bupivacaine (5 mg) + 15 mcg fentanyl intrathecal” NCT03993314 ↗ “Drug: High dose propofol, fentanyl and sevoflurane Deep Anesthesia” NCT05380778 ↗ “intra venous Narcotic drugs (fentanyl) in the dose of (1-2mcg/kg)” NCT03866733 ↗ “25, 35 mcg of Fentanyl (Fentanyl, Janssen Cilag, amp. 50 mcg/ml)” NCT02385539 ↗ “This group will receive fentanyl in the induction of anesthesia.” NCT03212456 ↗ “Propofol 2-3mg/kg, Fentanyl 1-2mcg/kg and Cisatracurium 0.2mg/kg” NCT04894864 ↗ “Fentanyl 10 microg/ml at continuous flow of 10 to 20 microg/hour” NCT01607996 ↗ “Fentanyl is administered at induction - standard dose 5 mcg/kg.” NCT04338984 ↗ “Group 2: PCEA with fentanyl 1 mcg/mL plus bupivacaine 0.8 mg/mL” NCT01074190 ↗ “propofol 1 mg/kg and fentanyl 1µg/kg will be administered IV” NCT06656455 ↗ “Initially, fentanyl was administered at a dose of 2-3 mcg/kg” NCT06816173 ↗ “Conventional sedation receiving analgosedation with fentanyl” NCT05559970 ↗ “0.1% Bupivacaine and 2microgram\\ml Fentanyl every one hour” NCT06494280 ↗ “intravenous administration of fentanyl 2µg/kg and propofol” NCT03600454 ↗ “Spinal anesthesia with bupivacaine 12.5 mg+fentanyl 15 ug” NCT03639389 ↗ “Fentanyl 1 to 2 mcg/kg followed by IV lidocaine infusion” NCT07116564 ↗ “Fentanyl * IV bolus of 1 µg/kg for sedation induction” NCT01840371 ↗ “50 micrograms of fentanyl given before the procedure” NCT01786434 ↗ “followed by an opioid such as fentanyl (1-2 mcg/kg)” NCT05509192 ↗ “fentanyl 100 μg will be administered intravenously.” NCT07588802 ↗ “Morphine, oxycodone, metadone, fentanyl, tramadol” NCT03365817 ↗ “DepoDur with on demand boluses of IV fentanyl PCA” NCT00728832 ↗ “fentanyl was administered at a dose of 2 mcg/kg” NCT06779968 ↗ “etomidate, fentanyl (1-2 mcg/kg) and rocuronium” NCT01566838 ↗ “Group 1: Levobupivacaine 8 mg + 20 mcg Fentanyl” NCT03956303 ↗ “intrathecal bupivacaine 0.5% 15mg and fentanyl” NCT05602038 ↗ “fentanyl 1 mcg/kg followed by 1 -2 mcg/kg/h” NCT05962671 ↗ “fentanyl 50-100 mcg IV prior to intubation” NCT07211399 ↗ “0.0625% Bupivacaine plus fentanyl 2mcg/ml” NCT02887222 ↗ “Only received fentanyl IV during surgery.” NCT03879980 ↗ “Epidural fentanyl 200 microgram bolus” NCT00848419 ↗ “IV sedation with fentanyl and versed” NCT03187002 ↗ “propofol 2mg /kg ,fentanyl 2 mic/ kg” NCT05825430 ↗ “Bupivacaine 0.1%, fentanyl 1 mic/kg” NCT00801047 ↗ “Opioid based group receive fentanyl” NCT07360327 ↗ “fentanyl 1 mcg/kg before induction” NCT01584570 ↗ “2 mcg/kg fentanyl in 10 ml volume” NCT05752799 ↗ “Fentanyl rescue dose (1mcg/kg)” NCT07568938 ↗ “Transdermal Opioid (Fentanyl)” NCT03472469 ↗ “Fentanyl 2-4 mcg/kg IV bolus” NCT04197570 ↗ “intravenous fentanyl boluses” NCT01571791 ↗ “IV Fentanyl and midazolam” NCT06899724 ↗ “fentanyl (opioid agonist)” NCT04689217 ↗ “2. Recommended Fentanyl” NCT01315158 ↗ “Transdermal fentanyl” NCT00916890 ↗ “-Fentanyl: 10 mic\ml” NCT02121951 ↗ “Fentanyl: 1mcg/kg iv” NCT07558226 ↗ “Fentanyl (50mcg IV)” NCT04081545 ↗ “Fentanyl 1-2ug/kg” NCT01474252 ↗ “IV PCA(fentanyl)” NCT05053308 ↗ “Fentanyl 10ug” NCT01511627 ↗ “Fentanyl” NCT02886286 ↗ “Fentanyl” NCT06930183 ↗ “fentanyl” NCT03029676 ↗ |
| Known as | Abstral | “Ten minutes before the procedure fentanyl sublingual tablet (Abstral ® 100 µg, ProStrakan) will be given to the patient.” NCT01604187 ↗1“Abstral” NCT03080324 ↗ |
| Known as | Actiq | “Actiq® 400 µg is a solid formulation of fentanyl citrate on a plastic stick that dissolves slowly in the mouth for absorption across the buccal mucosa.” NCT01780233 ↗3“Fentanyl (Actiq®, Duragesic®, Fentora®, Lazanda®, Subsys®, and others)” NCT06240390 ↗ “ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC])” NCT00236093 ↗ “ACTIQ (Oral transmucosal fentanyl citrate)” NCT00236145 ↗ |
| Known as | AD 923 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00635063 ↗ |
| Known as | AeroLEF | “Study Evaluating Inhaled AeroLEF (Liposome-Encapsulated Fentanyl)in Normal Healthy Subjects” NCT00708318 ↗1“one dose (5mL) of inhaled AeroLEF (500 mcg/mL as fentanyl base)” NCT00794209 ↗ |
| Known as | BEMA Fentanyl | “Study of the Safety of BEMA™ Fentanyl Use for Breakthrough Pain in Cancer Subjects on Chronic Opioid Therapy” NCT00293020 ↗ |
| Known as | Breakyl | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Colgate total toothpaste | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05868200 ↗ |
| Known as | Control Group | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02592278 ↗ |
| Known as | Duragesic | “This is an Open-label, Non-Randomized, 3-way Crossover Bioequivalence Study to compare fentanyl release after heating of a brand name (Duragesic) and generic (Apotex and Mylan)...” NCT02486016 ↗8“For patients who were using transdermal fentanyl (ie,Duragesic®), the initial dose of ZR-02-01 was the same as their current Duragesic dose.” NCT00126763 ↗ “In addition, fentanyl is currently marketed for transdermal use (Duragesic fentanyl transdermal patch) for the management of chronic pain.” NCT00714558 ↗ “Study of the Effect of Clinical Procedures on Drug Delivery of Mylan Fentanyl Transdermal System 25 µg/hr and Duragesic® 25 µg/hr” NCT00648414 ↗ “Fentanyl (Actiq®, Duragesic®, Fentora®, Lazanda®, Subsys®, and others)” NCT06240390 ↗ “Duragesic® (fentanyl) Transdermal Therapeutic System (TTS)” NCT00271414 ↗ “then wore a Duragesic® fentanyl TDDS (25 µg/h) for 72 h” NCT02531971 ↗ “Duragesic® (Fentanyl Transdermal System)” NCT00237341 ↗ “Duragesic (fentanyl transdermal system)” NCT00650182 ↗ |
| Known as | Duragesic fentanyl skin patch | “Duragesic® fentanyl skin patch” NCT02531971 ↗ |
| Known as | Duragesic-100 | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Duragesic-12 | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Duragesic-25 | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Duragesic-37 | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Duragesic-50 | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Duragesic-75 | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Duragesic | “Duragesic® (fentanyl) Therapeutic Transdermal System (TTS)” NCT00271466 ↗ |
| Known as | Durogesic | “Open-Label Study To Assess The Effect On Pain Control Of Durogesic (Fentanyl Transdermic Therapeutic System) Treatment In Subjects With Rheumatoid Arthritis Or Osteoarthritis...” NCT00524160 ↗2“One DUROGESIC transdermal patch containing 8.4 mg of fentanyl applied on the skin for 72 hours.” NCT01717157 ↗ “Durogesic® (fentanyl transdermal drug delivery system)” NCT00271453 ↗ |
| Known as | Durogesic d-trans | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Effentora | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | EN3267 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00263575 ↗ |
| Known as | engineered HB vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00939068 ↗ |
| Known as | FBT | “Previous single-dose studies found that prophylactic administration of fentanyl buccal tablet (FBT) improved exertional dyspnoea.” PMID 41115797 ↗ Mar 20262“Fentanyl buccal tablets (FBT) placed in the buccal cavity above a rear molar until disintegrated, approximately 14-25 minutes.” NCT00387010 ↗ “A Preliminary Study of Prophylactic Fentanyl Buccal Tablets (FBT) for Exercise Induced Breakthrough Dyspnea” NCT01856114 ↗ |
| Known as | FCIV | “Fentanyl Citrate IV (FCIV)” NCT02576353 ↗ |
| Known as | FEN | “Drug: Fentanyl (FEN)” NCT07556133 ↗ |
| Known as | Fencino | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Fendrop | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Fentalis reservoir | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Fentanest | “Fentanest® 25 mcg/h. Each patch delivers 25 mcg of fentanyl per hour continuously for 72 hours.” NCT00959400 ↗ |
| Known as | fentanil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03966326 ↗ |
| Known as | FENTANILE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02909049 ↗ |
| Known as | FENTANILE 0,05 mg/ml ATC N01AH01 MAN 41764 | “FENTANILE 0,05 mg/ml ATC N01AH01 MAN 41764” NCT02909049 ↗ |
| Known as | Fentanilo | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Fentanyl (Fentanyl Citrate) | “Fentanyl (Fentanyl Citrate)” NCT07267377 ↗ |
| Known as | Fentanyl buccal | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Fentanyl Buccal Tablets | “A Preliminary Study of Prophylactic Fentanyl Buccal Tablets (FBT) for Exercise Induced Breakthrough Dyspnea” NCT01856114 ↗ |
| Known as | Fentanyl cii | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Fentanyl Citrate | “Initiated dose of 0.3ml/kg of Bupivacaine Hydrochloride 1.25mg/ml and Fentanyl Citrate 2 micrograms/ml was administered then continued PCA (Perfusor space pump,Germany)with...” NCT03242668 ↗39“Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related...” NCT00343733 ↗ “Fentanyl citrate is an opioid strong analgesic that is particularly well suited for use in anesthesia because of its high potency, rapid onset and short duration of action” NCT07425444 ↗ “during which patients received sublingual fentanyl citrate orally disintegrating tablet (sublingual fentanyl ODT) or placebo, in a random order.” PMID 19814586 ↗ Dec 2009 “Fentanyl citrate (0.05 mg/ml) (Fentanyl Hameln pharmaceutical, Germany) (Low Dose) low dose fentanyl iv 1 microgram per kg before induction” NCT07533643 ↗ “Treatment A: Fentanyl citrate (equivalent to 80 mcg fentanyl) administered over 20 minutes by IV infusion every hour through 23.33 hours.” NCT01750060 ↗ “a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer.” PMID 24508417 ↗ Feb 2014 “Solution of fentanyl citrate (DIN : 02384124 / 02240434 / 02385406) will be administered sublingually by syringe.” NCT04004117 ↗ “to characterize the pharmacokinetics profile of ACTIQ (fentanyl citrate) in these children” NCT00236041 ↗ “Volunteers received a single-dose of 100 µg fentanyl citrate infusion” NCT02531971 ↗ “100 mcg fentanyl citrate will be inhaled via nebulizer.” NCT03018756 ↗ “ACTIQ (Oral transmucosal fentanyl citrate)” NCT00236145 ↗ “Fentanyl Citrate Buccal Tablet” NCT04188418 ↗ “Fentanyl Citrate (Intranasal)” NCT07112430 ↗ “ORAVESCENT Fentanyl Citrate” NCT00214942 ↗ “ORAVESCENT Fentanyl Citrate” NCT00214955 ↗ “KW-2246 (fentanyl citrate)” NCT00684632 ↗ “Fentanyl Citrate IV (FCIV)” NCT02576353 ↗ “KW-2246 (fentanyl citrate)” NCT00683995 ↗ “Drug: Fentanyl Citrate” NCT00795314 ↗ “Drug: Fentanyl Citrate” NCT05051189 ↗ “Drug: Fentanyl Citrate” NCT06051227 ↗ “Drug: Fentanyl Citrate” NCT05437575 ↗ “Drug: Fentanyl Citrate” NCT04199013 ↗ “Drug: Fentanyl Citrate” NCT01853449 ↗ “Drug: Fentanyl Citrate” NCT04645823 ↗ “Drug: Fentanyl Citrate” NCT03405090 ↗ “Drug: Fentanyl Citrate” NCT01482091 ↗ “Drug: Fentanyl Citrate” NCT03682211 ↗ |
| Known as | Fentanyl citrate cii | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Fentanyl citrate component of innovar | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Fentanyl Citrate Injection, USP (Fentanyl) | “Fentanyl Citrate Injection, USP (Fentanyl)” NCT01050699 ↗ |
| Known as | Fentanyl Citrate Nasal Spray | “Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)” NCT07120763 ↗2“Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)” NCT00459277 ↗ “Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)” NCT00458510 ↗ |
| Known as | Fentanyl citrate preservative free | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Fentanyl Citrate USP | “single dose of intravenous Fentanyl Citrate USP (200 mcg)” NCT00794209 ↗ |
| Known as | Fentanyl component of tranq | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Fentanyl Ethypharm | “a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer.” PMID 24508417 ↗ Feb 2014 |
| Known as | Fentanyl Hameln | “will be given 0.5 ml of one ampoule (2ml) of 100µg fentanyl (Fentanyl Hameln® 0.1mg/2ml - Sunny pharm) equivalent to 25 µg fentanyl as an adjuvant to 2.2ml hyperbaric...” NCT06318546 ↗1“Fentanyl (Fentanyl Hameln® 0.1mg/2ml) 25 mcg will be given intrathecally added to 4 ml (20 mg) of 0.5% hyperbaric bupivacaine” NCT06834841 ↗ |
| Known as | Fentanyl HCI | “Double-Blind, Placebo-Controlled Comparative Study of SyB P-1501 (Fentanyl HCI) for Treatment of Postoperative Pain” NCT03005899 ↗ |
| Known as | fentanyl HCl | “The purpose of this study is to evaluate the safety and clinical utility of fentanyl HCl 40 mcg system for the management of postoperative pain in pediatric inpatients.” NCT00666393 ↗4“Fentanyl HCl Patient-Controlled Transdermal System (E-TRANS fentanyl)” NCT00266539 ↗ “Fentanyl HCl and morphine are narcotic pain relievers.” NCT00264485 ↗ “IONSYS (fentanyl HCl) Iontophoretic TransdermalSystem” NCT00996177 ↗ “Drug: Fentanyl HCl” NCT05550597 ↗ |
| Known as | Fentanyl hydrochloride | “One patch of SyB P-1501 contains 10.8 mg of fentanyl hydrochloride (fentanyl 9.7 mg) and produces an electric current to deliver the drug iontophoretically after the system is...” NCT03005899 ↗2“E-TRANS Fentanyl hydrochloride; Morphine” NCT00266539 ↗ “Drug: Fentanyl Hydrochloride” NCT02953210 ↗ |
| Known as | fentanyl ITS | “The fentanyl iontophoretic transdermal system (fentanyl ITS) enables needle-free, patient-controlled analgesia for postoperative pain management.” PMID 17519263 ↗ Jun 2007 |
| Known as | Fentanyl SL Spray | “Open-label Multi-center Safety Trial of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain” NCT00538863 ↗ |
| Known as | Fentanyl Sublingual Spray | “Drug: Fentanyl Sublingual Spray” NCT02597478 ↗1“Fentanyl Sublingual Spray (FSS)” NCT02576353 ↗ |
| Known as | Fentanyl Transdermal System | “Duragesic® (Fentanyl Transdermal System)” NCT00237341 ↗1“Drug: Fentanyl Transdermal System” NCT04204967 ↗ |
| Known as | Fentanyl WZF | “intraoperative rescue opioid analgesia using 1mcg/kg of fentanyl (Fentanyl WZF, POlfa Warsawa, Poland)” NCT06609993 ↗ |
| Known as | Fentanyl, 50μg/ml, Janssen-Cilag, Belgium | “Fentanyl, 50μg/ml (Janssen-Cilag, Belgium)” NCT01558713 ↗1“Fentanyl, 50μg/ml, Janssen-Cilag, Belgium” NCT01582607 ↗ |
| Known as | Fentanyl, Hameln (ATC code: N01A H01) | “Fentanyl, Hameln (ATC code: N01A H01)” NCT05639712 ↗1“Fentanyl "Hameln" ATC-code: N01AH01” NCT01934088 ↗ |
| Known as | Fentanyl-100 | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Fentanyl-12 | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Fentanyl-25 | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Fentanyl-37 | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Fentanyl-50 | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Fentanyl-62 | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Fentanyl-75 | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Fentanyl-87 | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Fentanyl-TTS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01902524 ↗ |
| Known as | Fentora | “Fentanyl (Actiq®, Duragesic®, Fentora®, Lazanda®, Subsys®, and others)” NCT06240390 ↗ |
| Known as | FITpatch | “Transdermal Fentanyl (FITpatch)” NCT00279344 ↗ |
| Known as | FNT | “Drug: Fentanyl (FNT). Intraoperative administration of fentanyl given as one single bolus dose of 50 μg at the time of induction of anesthesia.” NCT02619032 ↗ |
| Known as | FPNS | “Fentanyl pectin nasal spray (FPNS)” NCT01980498 ↗ |
| Known as | FSS | “Fentanyl sublingual spray (FSS) packaged to deliver 100 µg/spray, 200 µg/spray or 400 µg/spray” NCT02138409 ↗ |
| Known as | Greenplast | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05645198 ↗ |
| Known as | IDS-NF-001 | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | INF | “OBJECTIVE: Intranasal fentanyl (INF) quickly and noninvasively relieves severe
pain, whereas intravenous hydromorphone (IVH) reliably treats severe cancer pain but requires...” PMID 32649717 ↗ Jul 20201“intranasal fentanyl (INF) is effective for rapidly decreasing MSK-I related pain in children” NCT02985177 ↗ |
| Known as | INFS | “intranasal fentanyl spray* (INFS) 400 μg” PMID 25641199 ↗ Jan 20151“Intranasal Fentanyl Spray (INFS)” NCT01497288 ↗ |
| Known as | Innovar | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Instanyl | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | IONSYS | “An Open-Label Evaluation of Safety of the IONSYS System [Fentanyl Iontophoretic Transdermal System (40ug) for Management of Acute Post-Operative Pain in Pediatric Patients” NCT00666393 ↗1“IONSYS (fentanyl HCl) Iontophoretic TransdermalSystem” NCT00996177 ↗ |
| Known as | JNS020QD | “One-day adhesive transdermal patch (patch containing a drug that is put on the skin so the drug will enter the body through the skin) containing fentanyl (JNS020QD) applied to...” NCT01008553 ↗ |
| Known as | KW-2246 | “KW-2246 (fentanyl citrate)” NCT00684632 ↗ |
| Known as | Lazanda | “Fentanyl (Actiq®, Duragesic®, Fentora®, Lazanda®, Subsys®, and others)” NCT06240390 ↗ |
| Known as | Leptanal | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Martindale pharma Fentanyl | “20 mcg of "Fentanyl," "Martindale pharma Fentanyl®," 50mcg/ml (0.4ml)” NCT06769737 ↗ |
| Known as | Matrifen | “Fentanyl (Matrifen)” NCT00279344 ↗ |
| Known as | MCN-JR-4263-49 | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Mezolar matrix | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Mylafent | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Mylan Fentanyl Transdermal System | “Study of the Effect of Clinical Procedures on Drug Delivery of Mylan Fentanyl Transdermal System 25 µg/hr and Duragesic® 25 µg/hr” NCT00648414 ↗ |
| Known as | Mylan generic fentanyl | “Mylan generic fentanyl” NCT02531971 ↗ |
| Known as | Mylan generic fentanyl skin patch | “Mylan generic fentanyl skin patch” NCT02531971 ↗ |
| Known as | N02AB03 | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Narco | “subligual fentanyl(Narco®) Fentanyl 100mcg/200mcg/300mcg according to the around-the-clock opioid requirement.” NCT05053308 ↗ |
| Known as | Nasalfent | “Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)” NCT07120763 ↗2“Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)” NCT00459277 ↗ “Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)” NCT00458510 ↗ |
| Known as | Onsolis | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Onsolis (fentanyl buccal soluble film) | “Onsolis (fentanyl buccal soluble film)” NCT00293033 ↗ |
| Known as | Opiodur | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Oral isotretinoin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04156815 ↗ |
| Known as | Oral Transmucosal Fentanyl Citrate | “ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC])” NCT00236093 ↗ |
| Known as | Oralet | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | OraVescent | “ORAVESCENT Fentanyl Citrate” NCT00214942 ↗ |
| Known as | OraVescent Fentanyl | “Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related...” NCT00343733 ↗ |
| Known as | Osmach | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Osmanil | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | OTFC | “ACTIQ® (Oral Transmucosal Fentanyl Citrate [OTFC®]) Treatment for Opioid-Tolerant Children and Adolescents With Breakthrough Pain” NCT00236041 ↗1“ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC])” NCT00236093 ↗ |
| Known as | OVF | “OraVescent fentanyl (OVF)” NCT00105287 ↗ |
| Known as | Painkyl, fentanyl buccal soluble film (FBSF) | “Painkyl, fentanyl buccal soluble film (FBSF)” NCT03669263 ↗ |
| Known as | PecFent | “PecFent will be supplied by Archimedes Pharma as two strengths of nasal spray solution at 1000 or 4000 mcg/mL fentanyl (as citrate).” NCT02009306 ↗2“Medication Commercial name Formulation Administration route Dose Fentanyl citrate Pecfent® Nasal spray Intranasal 100 µg” NCT03809455 ↗ “Safety of Intranasal Fentanyl (PecFent®) in the Treatment of Procedural Pain in the Elderly” NCT02298582 ↗ |
| Known as | Phentanyl | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | R 4263 | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Recivit | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Recuvyra | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Silver ions dressing | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05368142 ↗ |
| Known as | Staccato Fentanyl | “Inhaled Staccato Fentanyl, 25 mcg x 1 dose” NCT00402350 ↗ |
| Known as | Sublimase | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Sublimaze | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Sublimaze preservative free | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Subsys | “Fentanyl (Actiq®, Duragesic®, Fentora®, Lazanda®, Subsys®, and others)” NCT06240390 ↗1“sublingual fentanyl spray (Subsys)” NCT02241486 ↗ |
| Known as | Thalamonal | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Tilofyl | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | TTS fentanyl | “This is an open label (all people know the identity of the intervention), single arm, prospective (study following participants forward in time) study conducted to assess the...” NCT01774903 ↗3“TTS fentanyl (a transdermal patch delivering the narcotic pain reliever fentanyl)” NCT00269737 ↗ “TTS-fentanyl patches releasing at the rate of 12.5 microgram per hour for 3 days.” NCT01774929 ↗ “therapeutic transdermal fentanyl system (TTS-fentanyl)” PMID 11591092 ↗ Sep 2001 |
| Known as | Victanyl | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | Yemex | ChEMBL registry synonym — accepted as the source's own label CHEMBL596 ↗ |
| Known as | ZR-02-01 | “ZR-02-01 Fentanyl Transdermal Matrix Patch” NCT00108771 ↗ |
| Known as | β-tricalcium phosphate Injectable Bone Graft | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07368114 ↗ |
| Action | Activate | “Fentanyl is a synthetic pure opioid agonist with a selective activity on µ receptors.” NCT00523887 ↗1“Mu opioid receptor agonist” CHEMBL596 ↗ |
| Modality | Other / unclassified | “Fentanyl HCl and morphine are narcotic pain relievers.” NCT00264485 ↗ |
| Route | Intravenous | “The current double-blind, placebo-controlled in-patient study was designed to compare the effects of intravenously delivered fentanyl (0, 0.0625, 0.125, 0.187, and 0.250 mg/70...” PMID 17581533 ↗ Jun 2007 |
| Target | OPRM1 | “Mu opioid receptor agonist” CHEMBL596 ↗ |